Aurobindo Pharma

62
Hold
  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE406A01037
  • NSEID: AUROPHARMA
  • BSEID: 524804
INR
1,220.60
-3.05 (-0.25%)
BSENSE

Dec 05

BSE+NSE Vol: 2.35 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationProfit and Loss Results
Results Snapshot
Figures in Cr
Consolidated - Profit And Loss Results
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Mar'19
No of Months
12
12
12
12
12
12
Operating Income
29,001.00
24,855.00
23,455.00
24,774.00
23,098.00
19,563.00
Less :Inter divisional transfers
0.00
0.00
0.00
0.00
0.00
0.00
Less: Excise
0.00
0.00
0.00
0.00
0.00
0.00
Net Sales
29,001.00
24,855.00
23,455.00
24,774.00
23,098.00
19,563.00
Expenditure (Ex Depriciation)
Stock Adjustments
-946.00
-409.00
816.00
-730.00
-101.00
-675.00
Raw Materials Consumed
13,549.00
11,702.00
9,323.00
10,632.00
9,837.00
9,388.00
Power & Fuel Cost
826.00
842.00
626.00
589.00
587.00
556.00
Employee Cost
3,922.00
3,522.00
3,450.00
3,535.00
3,219.00
2,584.00
Operating Expenses
1,142.00
1,026.00
1,058.00
1,109.00
964.00
953.00
General and Administration Expenses
-1.00
-1.00
-1.00
-1.00
-1.00
-1.00
Selling and Distribution Expenses
1,684.00
1,685.00
1,496.00
1,564.00
1,524.00
1,125.00
Cost of Software developments
0.00
0.00
0.00
0.00
0.00
0.00
Miscellaneous Expenses
691.00
746.00
459.00
666.00
565.00
439.00
Expenses Capitalised
0.00
0.00
0.00
0.00
0.00
0.00
Total Expenditure
23,158.00
21,136.00
19,068.00
19,441.00
18,234.00
15,611.00
Operating Profit (PBDIT) excl Other Income
5,843.00
3,718.00
4,386.00
5,333.00
4,864.00
3,951.00
Other Income
557.00
290.00
320.00
380.00
191.00
155.00
Operating Profit (PBDIT)
6,400.00
4,009.00
4,707.00
5,714.00
5,056.00
4,107.00
Interest
289.00
140.00
48.00
74.00
305.00
262.00
Profit before Depriciation and Tax
6,110.00
3,868.00
4,658.00
5,639.00
4,751.00
3,844.00
Depreciation
1,521.00
1,244.00
1,126.00
1,055.00
966.00
667.00
Profit Before Taxation & Exceptional Items
4,589.00
2,624.00
3,531.00
4,584.00
3,784.00
3,176.00
Exceptional Income / Expenses
0.00
0.00
0.00
0.00
0.00
0.00
Profit Before Tax
4,379.00
2,612.00
3,372.00
7,343.00
3,743.00
3,091.00
Provision for Tax
1,211.00
684.00
725.00
2,009.00
899.00
726.00
Profit After Tax
3,186.00
1,939.00
2,678.00
5,389.00
2,858.00
2,361.00
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
Adj to Profit After Tax
0.00
0.00
0.00
0.00
0.00
0.00
Profit Balance B/F
23,910.00
22,518.00
20,136.00
15,042.00
12,398.00
10,211.00
Profit Available for appropriations
27,083.00
24,446.00
22,784.00
20,377.00
15,243.00
12,576.00
Appropriations
27,083.00
24,446.00
22,784.00
20,377.00
15,243.00
12,576.00
Equity Dividend (%)
450.00%
750.00%
900.00%
400.00%
300.00%
250.00%
Earnings Per Share
54.16
32.90
45.20
91.05
48.56
40.36
Profit And Loss Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Mar 2025 is 2.70% vs -16.78% in Mar 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Mar 2025 is 15.00% vs 28.49% in Mar 2024

stock-summary

Interest

YoY Growth in year ended Mar 2025 is 25.98% vs 58.81% in Mar 2024

stock-summary

Profit After Tax

YoY Growth in year ended Mar 2025 is -8.07% vs 54.43% in Mar 2024

Compare Profit and Loss Results of Aurobindo Pharma
Markets Mojo
Figures in Cr
consolidated - Profit And Loss Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
No of Months
12
12
Operating Income
29,001.00
12,207.00
16,794.00
137.58%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
29,001.00
12,207.00
16,794.00
137.58%
Expenditure (Ex Depriciation)
Stock Adjustments
-946.00
-183.00
-763.00
-416.94%
Raw Materials Consumed
13,549.00
3,672.00
9,877.00
268.98%
Power & Fuel Cost
826.00
149.00
677.00
454.36%
Employee Cost
3,922.00
2,692.00
1,230.00
45.69%
Operating Expenses
1,142.00
246.00
896.00
364.23%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
1,684.00
1,164.00
520.00
44.67%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
691.00
161.00
530.00
329.19%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
23,158.00
9,186.00
13,972.00
152.10%
Operating Profit (PBDIT) excl Other Income
5,843.00
3,020.00
2,823.00
93.48%
Other Income
557.00
536.00
21.00
3.92%
Operating Profit (PBDIT)
6,400.00
3,557.00
2,843.00
79.93%
Interest
289.00
431.00
-142.00
-32.95%
Profit before Depriciation and Tax
6,110.00
3,125.00
2,985.00
95.52%
Depreciation
1,521.00
621.00
900.00
144.93%
Profit Before Taxation & Exceptional Items
4,589.00
2,504.00
2,085.00
83.27%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
4,379.00
2,516.00
1,863.00
74.05%
Provision for Tax
1,211.00
509.00
702.00
137.92%
Profit After Tax
3,186.00
1,994.00
1,192.00
59.78%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
23,910.00
9,918.00
13,992.00
141.08%
Profit Available for appropriations
27,083.00
11,905.00
15,178.00
127.49%
Appropriations
27,083.00
11,905.00
15,178.00
127.49%
Equity Dividend (%)
450%
0%
450.00
Earnings Per Share
54.16
49.28
4.88
9.90%
Profit And Loss - Net Sales
Net Sales 10,933.30 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 2.70% vs -16.78% in Mar 2024

Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 2,557.57 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 15.00% vs 28.49% in Mar 2024

Profit And Loss - Interest
Interest 230.04 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 25.98% vs 58.81% in Mar 2024

Profit And Loss - Profit After Tax
Profit After Tax 1,746.79 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is -8.07% vs 54.43% in Mar 2024